Icosagen

Tartu, Estonia

Biologics (mammalian) mAbs Bispecific/Multi-specific Antibodies Recombinant Proteins ADC (bioconjugation) Cell Line Development (CHO/HEK) Antibody Discovery

Program data pending ClinicalTrials.gov matching

60.0

Signal Score

○ FDA Inspections ○ Clinical Trials ○ SEC Filings ✓ Press (1) ○ EMA GMP ○ MHRA GMP

Quick Facts: Icosagen

Signal Score: 60.0/100
Quality Compliance: Assessment pending
Headquarters: Tartu, Estonia
Modalities: Biologics (mammalian), mAbs, Bispecific/Multi-specific Antibodies, Recombinant Proteins, ADC (bioconjugation), Cell Line Development (CHO/HEK), Antibody Discovery
Active Programs: No ClinicalTrials.gov matches confirmed
Data Sources: FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By: CDMO Signal — independent CDMO intelligence platform

About Icosagen

Auto-created by AI matchmaker. Data verification pending.

Signal Score & Pillar Breakdown

Quality Compliance —

No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.

FDA InspectionsNo US records on file

No FDA inspection records found for this manufacturer

Quality score requires FDA inspection data

Operations —

No ClinicalTrials.gov facility matches confirmed for this manufacturer.

Programs — no verified data

Sponsors— no verified data

ModalitiesBiologics (mammalian), mAbs, Bispecific/Multi-specific Antibodies, Recombinant Proteins, ADC (bioconjugation), Cell Line Development (CHO/HEK), Antibody Discovery

No clinical trial matches found for this manufacturer

Operational score requires ClinicalTrials.gov data

Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.

Financial Stability

Profile-based financial assessment

SEC FilingsPrivate company

Private company

Financial assessment: 60.0/100

Capacity

Profile-based capacity assessment

Recent Press1 articles

Broad modality coverage (7 modalities)